Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2003

View Archived Issues

Advances at Celltech summarized in preliminary announcement of 2002 results

New COX-2 inhibitors and their use patented by Pharmacia

Novel agents with AGE-breaking, AGE-inhibitory and free radical-scavenging activity

Shionogi BioResearch claims compounds with Taxol-enhancing activity

MitoKor synthesizes and tests new antiarthritic agents

Novel platelet ADP receptor inhibitors in Millennium development pipeline

Mochida researchers present novel tryptase inhibitors

Newly discovered thrombin inhibitors patented by Merck

Immunosuppressants from AstraZeneca with utility in obstructive airways diseases

Novel selective alpha4 integrin inhibitors covered by Celltech patent

Promising anticonvulsant activity of agmatine in rat seizure model

Selective NCX inhibitor reduces myocardial ischemic injury in rabbits

Zelandopam prevents cisplatin-induced renal failure in rats

Altana reports key product progress

Paxceed produces positive response in psoriasis patients

Preliminary phase II results, IND submitted for exenatide LAR in type 2 diabetes

Lantus approved in E.U. for pediatric use

OncoMab and Medarex join forces for cancer antibody development

Genzyme begins enrollment for Myozyme trial in Pompe's disease

Aderis receives DTI-0009 development milestone payment

New data on the safety profile of tadalafil in erectile dysfunction

WHO coordinates research on mysterious pneumonia-like disease

Promising preclinical findings for aplidine in leukemia and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Sept. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Sept. 18, 2025.
‘Prolific’ Regeneron won’t stop with phase III FOP data drop
BioWorld
“People have some inability to focus on [Regeneron Pharmaceuticals Inc.’s] pipeline,” which stands as “the most prolific in the industry, I would dare to say,”...
The ‘molecular revolution’ driving R&D of new cancer therapeutics
BioWorld Asia
“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...
Remynd’s REM-127 yields positive phase II data in Alzheimer’s
BioWorld
Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...